
Chuck Simonton
@drchucksimonton
Interventional Cardiologist and Innovator. CMO, Abiomed, Inc. Tweets represent my own opinion.
ID: 2899030105
14-11-2014 04:17:02
1,1K Tweet
3,3K Followers
547 Following

Now out in Journal of Cardiac Failure: A prospective, multi-center registry of Impella 5.5 in HF-CS: šbit.ly/4j8h171 š Treatment with Impella 5.5 alone vs. multiple MCSD associated with ā¬ļø survival and ā¬ļøcomplications š Patients bridged to HRT have 94% survival at 12- months



What a great ACC 1-year anniversary of the DanGer Shock RCT NEJM publication leading to upgrade of mAFP (Impella) to Class IIa by ACC/AHA/SCAI. So many informative sub-studies as well. Congrats again to Jacob MĆøller + investigators! Navin Kapur


My last day as CMO at Abiomed was quite memorable as Mike, Andrew, Devi (all prior or current Worldwide Presidents) and Jacob MĆøller (DanGer Shock) joined me in the studio for my CMO Corner show. What an honor itās been⦠Michael Minogue Navin Kapur Gregg W. Stone MD B. Hadley Wilson MD



Special day today at Carolinas Medical Center as Hadley Wilson was honored after āretiringā from the cath lab. He was my āwingmanā (and I was his) as we built PCI in the Carolinas. Here we are with Nyal Borges, now the PCI āmasterā at Sanger Clinic. B. Hadley Wilson MD Navin Kapur


The mechanistic plausibility of why these will work in HFrEF is highly compelling, and clearly displayed by the RELIEVE-HF data. Exciting times for HF patients. Navin Kapur

Canāt believe itās been 6 years!! Stakeholders in the field are clearly aligned by this ācommon languageā for staging cardiogenic shock. Now onward in your role at SCAI to setting standards to operationalize DanGer Shock and save lives! Gregg W. Stone MD Navin Kapur Babar Basir

On Memorial Day weekend, as you visit with family and friends, remember why you have what you have in the U.S.A. and never forgetā¦history teaches usā¦. Just visit Arlington; or Normandy where they never made it homeā¦God Bless these men and women⦠Michael Minogue Alex Truesdell


dlvr.it/TLG79F Many of us š our eyes out at news of this Raja Hatem Darshan Doshi, MD, MS Allen Jeremias William Nicholson Sanjog Kalra Amirali Masoumi David J. Cohen, MD, MSc #ajaykirtane. So many of us owed so much to him professionally and personally. I would never be where I am without him. He was the


Congrats. The big learning in this data is that the actual observed risk in Impella-supported HRPCI in over 1000 pts was half of what was predicted by either BCIS or NCDR PCI risk scores, suggesting outcome enhancement by Impella support. Fascinating. Gregg W. Stone MD Mamas A. Mamas

Really excited to see the great program put together by Allison Dupont, MD Sandeep Nathan, MD, MSc Behnam N. Tehrani, MD leaders in the CS space. If you want to continue to adv your CS team or need some help getting started please sign up for the pre-con ⦠scai.org/2025-scai-shocā¦

What an achievement by the PROTECT IV investigators! 4 years of enrollment preceded by 1 1/2 years of planning. The largest PCI strategy RCT in our fieldās hx, and oh how important for ischemic HFrEF patients. Now to complete 1-3 years f/u in all pts. Gregg W. Stone MD Navin Kapur

62yo man, NSTEMI, EF:21%, Mean PA: 35mmHg, PCWP:20mmHg, CPO: 0.56. Protected PCI w/ Impella CP for LM/LAD last remaining vessel. Impella was absolutely essential as the patient lost arterial pulsatility during vessel manipulation. Amazing performance of the device



Tnxs Cardiac Interventions Today for allowing me to share reflections on āA Decade of Quality Improvement: The National Cardiogenic Shock Initiativeā NCSIās recommendations have become the SOC for AMI-CS management post-Danger Iyad Isseh Ų„ŁŲ§ŲÆ ŁŲØŁŁ Ų§ŁŲ¹Ų³ŁŲ© David Wohns Alex Truesdell Link: citoday.com/articles/2025-ā¦


